ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ATP-competitive inhibitors targeting ABL1 have greatly improved the prognosis of CML patients, but drug resistance (Devos et al., 2021), disease progression (Kakiuchi et al., 2021), or some serious adverse events occurring during treatment bring challenges to clinical practices (Castagnetti et al., 2021; Clapper et al., 2021), especially drug resistance caused by BCR::ABL1 mutations (Mian et al., 2021).